Answers are grounded in this paper and cite their sources.
Contemporary immunosuppressive and anticancer therapies have broadened the population at risk of developing Pneumocystis pneumonia (PCP) among adults without HIV. Compared with HIV-associated PCP, disease in this population is characterized by a lower organism burden with more rapid hypoxemic deterioration, and host comorbidities and concurrent therapies may limit treatment tolerance. This focused narrative review addresses three linked problems: diagnostic uncertainty, treatment-limiting toxicity, and individualized management. Diagnosis requires assessment of the probability rather than binary interpretation as present or absent based on Pneumocystis detection, integrating immune trajectory and prophylaxis received with imaging and oxygenation, specimen adequacy, PCR results, serum β-D-glucan, and competing diagnoses. Trimethoprim/sulfamethoxazole remains the first-line therapy, but organ dysfunction and treatment-emergent toxicity may prevent completion of treatment. Reduced-dose strategies may improve tolerability but are not established as a universal replacement for conventional dosing; apparent treatment failure should prompt reassessment of the working diagnosis and evaluation for co-infection. Current evidence does not support routine use of adjunctive corticosteroids for all patients. Selective use may be considered when evidence of PCP is strong, acute hypoxemic respiratory failure is present and competing causes of deterioration have been assessed. Primary and secondary prophylaxis should be reassessed as immune status, treatment phase, and tolerance evolve. A structured, standards-based approach applied at treatment initiation, early reassessment, and treatment completion or discharge, provides a practical framework for individualized care.
No takes yet. Share an insight, caveat, or question.
Nakashima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: